Related Experiment Video
Updated: Oct 10, 2025

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Small Dense Low-Density Lipoprotein Cholesterol and Cardiovascular Risk in Statin-Treated Patients with Coronary
Junnichi Ishii1, Kosuke Kashiwabara2, Yukio Ozaki3
1Department of Clinical Laboratory, Bantane Hospital, Fujita Health University School of Medicine.
Insights
Small dense low-density cholesterol (sdLDL-C) is linked to cardiovascular risk in statin-treated patients. High-dose statin therapy effectively lowers this risk for individuals with the highest sdLDL-C levels.
Area of Science:
- Cardiology
- Lipid Metabolism
- Pharmacotherapy
Background:
- Small dense low-density cholesterol (sdLDL-C) is an independent risk factor for cardiovascular disease.
- Statin therapy is a cornerstone in managing coronary artery disease (CAD), but its effectiveness may vary based on lipid profiles.
Purpose of the Study:
- To investigate the association between sdLDL-C levels and the risk of major adverse cardiovascular events (MACE) in patients with stable CAD receiving high- or low-dose statin therapy.
- To determine if high-dose statin therapy offers differential benefits in reducing MACE based on baseline sdLDL-C levels.
Main Methods:
- A prospective case-cohort study was conducted within the REAL-CAD randomized trial.
- Serum sdLDL-C was measured at baseline and 6 months in 497 MACE cases and 1543 randomly selected participants.
- Patients received either high-dose (4 mg/d) or low-dose (1 mg/d) pitavastatin.
Main Results:
- High-dose pitavastatin significantly reduced sdLDL-C compared to low-dose therapy.
- In patients on low-dose statins, higher baseline sdLDL-C was associated with increased MACE risk, independent of LDL-C.
- High-dose statins reduced MACE risk by 46% in the highest sdLDL-C quartile but increased risk in the lowest quartile, indicating a significant interaction.
Conclusions:
- sdLDL-C is a significant predictor of cardiovascular risk in statin-treated CAD patients, independent of LDL-C.
- High-dose statin therapy mitigates cardiovascular risk in patients with elevated baseline sdLDL-C.
- The findings highlight the importance of assessing sdLDL-C for personalized statin therapy selection in CAD patients.
Aim:
We investigated the relationship between small dense low-density cholesterol (sdLDL-C) and risk of major adverse cardiovascular events (MACE) in patients treated with high- or low-dose statin therapy.
Methods:
This was a prospective case-cohort study within the Randomized Evaluation of Aggressive or Moderate Lipid-Lowering Therapy with Pitavastatin in Coronary Artery Disease (REAL-CAD) study, a randomized trial of high- or low-dose (4 or 1 mg/d pitavastatin, respectively) statin therapy, in patients with stable coronary artery disease (CAD). Serum sdLDL-C was determined using an automated homogenous assay at baseline (randomization after a rule-in period, >1 month with 1 mg/d pitavastatin) and 6 months after randomization, in 497 MACE cases, and 1543 participants randomly selected from the REAL-CAD study population.
Results:
High-dose pitavastatin reduced sdLDL-C by 20% than low-dose pitavastatin (p for interaction <0.001). Among patients receiving low-dose pitavastatin, baseline sdLDL-C demonstrated higher MACE risk independent of LDL-C (hazard ratio [95% confidence interval], 4th versus 1st quartile, 1.67 [1.04-2.68]; p for trend=0.034). High-dose (versus low-dose) pitavastatin reduced MACE risk by 46% in patients in the highest baseline sdLDL-C quartile (>34.3 mg/dL; 0.54 [0.36-0.81]; p=0.003), but increased relative risk by 40% in patients with 1st quartile (≤ 19.5 mg/dL; 1.40 [0.94-2.09]; p=0.099) and did not alter risk in those in 2nd and 3rd quartiles (p for interaction=0.002).
Conclusions:
These findings associate sdLDL-C and cardiovascular risk, independent of LDL-C, in statin-treated CAD patients. Notably, high-dose statin therapy reduces this risk in those with the highest baseline sdLDL-C.
More Related Videos
07:29Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
Published on: October 12, 2017
08:45LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
Published on: November 17, 2018
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Coronary Artery Disease IV: Preventive Measures
Atherosclerosis III: Management
Blood Studies for Cardiovascular System III: Serum Lipid Profile
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT
Cholesterol: Significance and Regulation
Considering cholesterol and...